TCF7L2 genotype and α-cell function in humans without diabetes

Diabetes

Volumn 65, Issue 2, 2016, Pages 371-380

  Shah, Meera ^a   Varghese, Ron T ^a   Miles, John M ^a   Piccinini, Francesca ^b   Dalla Man, Chiara ^b   Cobelli, Claudio ^b   Bailey, Kent R ^a   Rizza, Robert A ^a   Vella, Adrian ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCAGON; GLUCOSE; GLYCEROL; HEPARIN; INSULIN; TRANSCRIPTION FACTOR 7 LIKE 2; EMULSION; PHOSPHOLIPID; SOYBEAN OIL; SOYBEAN OIL, PHOSPHOLIPID EMULSION; TCF7L2 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; FEMALE; GENE LOCUS; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GLUCOSE TOLERANCE; HOMOZYGOTE; HUMAN; HUMAN CELL; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; COHORT ANALYSIS; DIABETES MELLITUS; DRUG EFFECTS; EMULSION; GENETIC VARIATION; GENETICS; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; PHARMACOLOGY; PHYSIOLOGY; SECRETION (PROCESS);

ADULT; AGED; ALLELES; COHORT STUDIES; DIABETES MELLITUS; EMULSIONS; FATTY ACIDS, NONESTERIFIED; FEMALE; GENETIC VARIATION; GENOTYPE; GLUCAGON; GLUCAGON-SECRETING CELLS; GLUCOSE TOLERANCE TEST; GLYCEROL; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PHOSPHOLIPIDS; SOYBEAN OIL; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 84962425236     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1233     Document Type: Article

References (48)

1. Talmud PJ, Cooper JA, Morris RW, et al.; UCLEB Consortium. Sixty-five common genetic variants and prediction of type 2 diabetes. Diabetes 2015; 64: 1830-1840
2. Florez JC, Jablonski KA, Bayley N, et al.; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355: 241-250
3. Saxena R, Hivert MF, Langenberg C, et al.; GIANT Consortium; MAGIC Investigators. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010; 42: 142-148
4. Waldhäusl W, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P. Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man. Diabetologia 1979; 17: 221-227
5. Cobelli C, Dalla Man C, Toffolo G, Basu R, Vella A, Rizza R. The oral minimal model method. Diabetes 2014; 63: 1203-1213
6. Xiang AH, Watanabe RM, Buchanan TA. HOMA and Matsuda indices of insulin sensitivity: poor correlation with minimal model-based estimates of insulin sensitivity in longitudinal settings. Diabetologia 2014; 57: 334-338
7. Pilgaard K, Jensen CB, Schou JH, et al. The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 2009; 52: 1298-1307
8. Elbein SC, Chu WS, Das SK, et al. Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent. Diabetologia 2007; 50: 1621-1630
9. Bock G, Dalla Man C, Campioni M, et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006; 55: 3536-3549
10. Cali AM, Man CD, Cobelli C, et al. Primary defects in beta-cell function further exacerbated by worsening of insulin resistance mark the development of impaired glucose tolerance in obese adolescents. Diabetes Care 2009; 32: 456-461
11. Utzschneider KM, Prigeon RL, Faulenbach MV, et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009; 32: 335-341
12. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10
13. Shah P, Vella A, Basu A, et al. Effects of free fatty acids and glycerol on splanchnic glucose metabolism and insulin extraction in nondiabetic humans. Diabetes 2002; 51: 301-310
14. Miles J, Glasscock R, Aikens J, Gerich J, Haymond M. A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res 1983; 24: 96-99
15. Miles JM, Ellman MG, McClean KL, Jensen MD. Validation of a new method for determination of free fatty acid turnover. Am J Physiol 1987; 252:E431-E438
16. Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C. Minimal model estimation of glucose absorption and insulin sensitivity from oral test: validation with a tracer method. Am J Physiol Endocrinol Metab 2004; 287:E637-E643
17. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 2001; 50: 150-158
18. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368-377
19. Cobelli C, Man CD, Sparacino G, Magni L, De Nicolao G, Kovatchev BP. Diabetes: models, signals, and control. IEEE Rev Biomed Eng 2009; 2: 54-96
20. Denti P, Toffolo GM, Cobelli C. The disposition index: from individual to population approach. Am J Physiol Endocrinol Metab 2012; 303:E576-E586
21. Cole TJ Sympercents: symmetric percentage differences on the 100 log(e) scale simplify the presentation of log transformed data. Stat Med 2000; 19: 3109-3125
22. Helgason A, Pálsson S, Thorleifsson G, et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 2007; 39: 218-225
23. Wegner L, Hussain MS, Pilgaard K, et al. Impact of TCF7L2 rs7903146 on insulin secretion and action in young and elderly Danish twins. J Clin Endocrinol Metab 2008; 93: 4013-4019
24. Kirchhoff K, Machicao F, Haupt A, et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 2008; 51: 597-601
25. Ingelsson E, Langenberg C, Hivert MF, et al.; MAGIC Investigators. Detailed physiologic characterization reveals diverse mechanisms for novel genetic loci regulating glucose and insulin metabolism in humans. Diabetes 2010; 59: 1266-1275
26. Liu PH, Chang YC, Jiang YD, et al. Genetic variants of TCF7L2 are associated with insulin resistance and related metabolic phenotypes in Taiwanese adolescents and Caucasian young adults. J Clin Endocrinol Metab 2009; 94: 3575-3582
27. Damcott CM, Pollin TI, Reinhart LJ, et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006; 55: 2654-2659
28. Butler PC, Rizza RA. Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 1991; 40: 73-81
29. Frank JW, Camilleri M, Thomforde GM, Dinneen SF, Rizza RA. Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans. Metabolism 1998; 47: 7-12
30. Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 1999; 277:E283-E290
31. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 4053-4059
32. Smushkin G, Sathananthan M, Sathananthan A, et al. Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1. Diabetes 2012; 61: 1082-1089
33. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007; 117: 2155-2163
34. Færch K, Pilgaard K, Knop FK, et al. Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele. Diabetes Obes Metab 2013; 15: 91-95
35. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008; 57: 678-687
36. Greenbaum CJ, Prigeon RL, D'Alessio DA. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes 2002; 51: 951-957
37. Bagger JI, Knop FK, Lund A, Holst JJ, Vilsbøll T. Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. Diabetologia 2014; 57: 1720-1725
38. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913
39. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 2005; 280: 1457-1464
40. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38: 320-323
41. Schäfer SA, Tschritter O, Machicao F, et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms [published corrections appear in Diabetologia 2008;51:208 and Diabetologia 2009; 52: 557]. Diabetologia 2007; 50: 2443-2450
42. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 2009; 18: 2388-2399
43. Le Bacquer O, Kerr-Conte J, Gargani S, et al. TCF7L2 rs7903146 impairs islet function and morphology in non-diabetic individuals. Diabetologia 2012; 55: 2677-2681
44. Munoz J, Lok KH, Gower BA, et al. Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in non-diabetic women. Diabetes 2006; 55: 3630-3634
45. Sathananthan A, Dalla Man C, Zinsmeister AR, et al. A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations. Clin Endocrinol (Oxf) 2012; 76: 212-219
46. Brownlie R, Mayers RM, Pierce JA, Marley AE, Smith DM. The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: investigations using GPR40-knockout mice. Biochem Soc Trans 2008; 36: 950-954
47. Nolan CJ, Madiraju MSR, Delghingaro-Augusto V, Peyot M-L, Prentki M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 2006; 55 (Suppl. 2):S16-S23
48. Smith EP, An Z, Wagner C, et al. The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab 2014; 19: 1050-1057